Oculis (NASDAQ:OCS) Stock Price Up 4.5% – What’s Next?

Oculis Holding AG (NASDAQ:OCS) traded up 4.5% on Tuesday . The stock traded as high as $15.50 and last traded at $15.45. 2,641 shares were traded during trading, a decline of 93% from the average session volume of 36,890 shares. The stock had previously closed at $14.79.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Oculis in a research report on Monday, November 11th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $29.20.

Oculis Price Performance

The company has a 50 day moving average price of $14.64 and a 200 day moving average price of $12.79. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. The firm has a market cap of $614.85 million, a PE ratio of -7.95 and a beta of -0.16.

Oculis (NASDAQ:OCS) last issued its earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.13). The firm had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.28 million. Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. Sell-side analysts expect that Oculis Holding AG will post -2.09 EPS for the current fiscal year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.